Drug Trial Radar · NCT06921837
A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer
Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
122
Planned (sponsor's estimate)
Start
May 26, 2025
Primary completion
May 2027
Study completion May 2029
Sponsor
- Lead sponsor
- Bolt Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A first-in-human study using BDC-4182 as a single agent in gastric and gastroesophageal cancers
Conditions
- Gastric Cancer Adenocarcinoma Metastatic
- Gastroesophageal Adenocarcinoma
Interventions
BDC-4182Drug
Immune stimulating antibody conjugate (ISAC), consisting of an anti-claudin 18.2 monoclonal antibody conjugated to a TLR 7/8 dual agonist
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs) and serious adverse events (SAEs) graded according to CTCAE v5.0Time frame: approximately 2 years
- Incidence and nature of AEs considered by the Investigator or Sponsor to be clinically relevant, attributable to study treatment, and meeting dose-limiting toxicity (DLT) criteriaTime frame: Up to 21 days
Locations
16 sites in 3 countries. Site status is shown where the registry gives one.
AUS Site 2
Darlinghurst, New South Wales, Australia · Recruiting
AUS Site 5
Westmead, New South Wales, Australia · Recruiting
AUS Site 1
Birtinya, Queensland, Australia · Recruiting
AUS Site 4
Clayton, Victoria, Australia · Recruiting
AUS Site 3
Heidelberg, Victoria, Australia · Recruiting
SK Site 2003
Seongnam-si, South Korea · Recruiting
SK Site 2001
Seoul, South Korea · Recruiting
SK Site 2002
Seoul, South Korea · Recruiting
SK Site 2004
Seoul, South Korea · Recruiting
SK Site 2005
Seoul, South Korea · Recruiting
TWN Site 9004
Kaohsiung City, Taiwan · Recruiting
TWN Site 9005
Kaohsiung City, Taiwan · Recruiting
TWN Site 9001
Taichung, Taiwan · Recruiting
TWN Site 9003
Taipei, Taiwan · Recruiting
TWN Site 9006
Taipei, Taiwan · Recruiting
TWN Site 9002
Taoyuan, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.